Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis
The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
Aims Glucagon is used to resolve severe hypoglycemia in unconscious patients with diabetes, requiring third-party assistance. A few studies have shown that intranasal (IN) glucagon causes resolution of hypoglycemia in insulin-treated patients with type 1 (T1DM) diabetes. This systematic review and meta-analysis updates the comparison of the effectiveness of IN glucagon with injected intramuscular/subcutaneous (IM/SC) glucagon in treatment of hypoglycemia in T1DM. Methods Controlled randomized studies were considered; eight studies, published in English, were included in a meta-analysis (random-effects model). Intervention effect (resolution of hypoglycemia) was expressed as odds ratio (OR), with 95% confidence intervals. Meta-regression was employed to correlate the effect with size of studies, age of patients, basal blood glucose levels. Results In a total of 467 treatments in 269 patients with IN and IM/SC glucagon, the OR IN versus IM/SC was 0.61 (CI 0.13-2.82); since four of eight studies showed 100% effectiveness, a simulation was made with 1 failure for each treatment; in this simulation analysis, the OR was 0.80 (95% CI 0.28-2.32). Heterogeneity was low and not statistically significant. Publication bias was absent, and quality of papers was high. At meta-regression, no correlation was found between the effect and number of patients in each study, age of patients, basal blood glucose levels. No study formally compared IN versus IM/SC in unconscious patients. Conclusion…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Kim, S. Y., Park, J. E., Lee, Y. J., Seo, H.-J., Sheen, S.-S., Hahn, S., Jang, B.-H., & Son, H.-J. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.09.016 · Cited by 1,165
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492
The T1D exchange clinic registry
Beck, R. W., Tamborlane, W. V., Bergenstal, R. M., Miller, K. M., DuBose, S. N., Hall, C. A., & for the T1D Exchange Clinic Network (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1561 · Cited by 456
Geller, A. I., Shehab, N., Lovegrove, M. C., Kegler, S. R., Weidenbach, K. N., Ryan, G. J., & Budnitz, D. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.136 · Cited by 305
Frequency and Morbidity of Severe Hypoglycaemia in Insulin‐treated Diabetic Patients
MacLeod, K. M., Hepburn, D. A., & Frier, B. M. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00051.x · Cited by 251
13. Children and Adolescents: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s013 · Cited by 200
Maternal Fear of Hypoglycemia in their Children with Insulin Dependent Diabetes Mellitus
Clarke, W. L., Gonder-Frederick, L. A., Snyder, A. L., & Cox (1998) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.1998.11.s1.189 · Cited by 159
Cognitive Dysfunction in Type 1 Diabetes Mellitus
Shalimova, A., Graff, B., Gąsecki, D., Wolf, J., Sabisz, A., Szurowska, E., Jodzio, K., & Narkiewicz, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01315 · Cited by 148
Parental fear of hypoglycemia: young children treated with continuous subcutaneous insulin infusion
Patton, S. R., Dolan, L. M., Henry, R., & Powers, S. W. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00242.x · Cited by 128
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 128
Sherr, J. L., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Rickels, M. R., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Fox, L. A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1606 · Cited by 122 · cited 2×
“…12 12 31 ± 2 31 ± 2 29 ± 6 29 ± 6 12 (100) 12 (100) Stenninger (1993)a SC 11 11 9 ± 2 9 ± 2 36 ± 6 40 ± 6 11 (100) 11 (100) Rickels (2016) IM 75 75 33 ± 12 33 ± 12 48 ± 8 49 ± 8 74 (99) 75 (100) Sherr (2016) IM 59 24 10 ± 10 10 ± 10 72 ± 8 72 ± 8 58 (98) 24 (100) Suico (2019)a IM 66 66 – – 59 ±…”
Driscoll, K. A., Volkening, L. K., Haro, H., Ocean, G., Wang, Y., Jackson, C. C., Clougherty, M., Hale, D. E., Klingensmith, G. J., Laffel, L., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12204 · Cited by 97
Yale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88
Glucagon administration – underevaluated and undertaught
Harrism, G., Diment, A., Sulway, M., & Wilkinson, M. (2001) · Practical Diabetes International · doi:10.1002/pdi.138 · Cited by 71 · cited 1×
“Based on evaluation of patient beliefs and patient expectations [28, 29], a Canadian pharmaceutical company in 2010 started to develop glucagon for IN administration.”
BackgroundIntranasal glucagon raises blood glucose concentrations in healthy volunteers.
Pontiroli, A. E., Alberetto, M., & Pozza, G. (1983) · BMJ · doi:10.1136/bmj.287.6390.462-a · Cited by 63
Self-citationStable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue
Wilson, L. M., & Castle, J. R. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757795 · Cited by 63
Pontiroli, A. E., Alberetto, M., Calderara, A., Pajetta, E., & Pozza, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558516 · Cited by 57 · cited 2×
“Pontiroli (1989) IM 15 15 35 ± 4 35 ± 4 45 ± 20 55 ± 20 14 (93) 14 (93) Slama (1990)a SC 3 3 30 ± 8 30 ± 8 38 ± 20 41 ± 20 3 (100) 3 (100) Slama (1992) SC 13 7 13 ± 3 13 ± 3 43 ± 15 58 ± 15 12 (92) 6 (86) Rosenfalck (1992)a IM 12 12 31 ± 2 31 ± 2 29 ± 6 29 ± 6 12 (100) 12 (100) Stenninger (1993)a…”
BackgroundSelf-citationSeaquist, E. R., Dulude, H., Zhang, X. M., Rabasa‐Lhoret, R., Tsoukas, G. M., Conway, J. R., Weisnagel, S. J., Gerety, G., Woo, V. C., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13278 · Cited by 54
Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population
Berra, C., Fazio, F. D., Azzolini, E., Albini, M., Zangrandi, F., Mirani, M., Garbossa, S., Guardado‐Mendoza, R., Condorelli, G., & Folli, F. B. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01323-8 · Cited by 51
Deeb, L. C., Dulude, H., Guzman, C. B., Zhang, S., Reiner, B. J., Piché, C. A., Pradhan, S., & Zhang, X. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12668 · Cited by 50
Pontiroli, A. E., Miele, L., & Morabito, A. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01543.x · Cited by 48
Self-citationNasal glucagon delivery using microcrystalline cellulose in healthy volunteers
Teshima, D., Yamauchi, A., Makino, K., Kataoka, Y., Arita, Y., Nawata, H., & Oishi, R. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00930-9 · Cited by 46
Pontiroli, A. E., Calderara, A., Pajetta, E., Alberetto, M., & Pozza, G. (1989) · Diabetes Care · doi:10.2337/diacare.12.9.604 · Cited by 41 · cited 2×
“[24] evaluated inpatients randomly allocated to IN glucagon or IM glucagon under two pre-specified conditions: blood glucose levels < 70 mg/dL plus subjective feeling of hypoglycemia.”
BackgroundMethodSelf-citationHeller, S. R. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.015 · Cited by 41
Pontiroli, A. E., Alberetto, M., & Pozza, G. (1985) · Acta Diabetologica · doi:10.1007/bf02590783 · Cited by 36
Self-citationBoido, A., Ceriani, V., & Pontiroli, A. E. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0665-0 · Cited by 34
Self-citationGlucose recovery after intranasal glucagon during hypoglycaemia in man
HVIDBERG, A. D., Djurup, R., & Hilsted, J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00195909 · Cited by 30
Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients
Rosenfalck, A. M., Bendtson, I., Jørgensen, S., & Binder, C. (1992) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(92)90042-p · Cited by 29 · cited 2×
“+ + − + + 2 Slama (1992) RCT + + + + + + 0 Rosenfalck (1992) RCT + + + − + + 1 Stenninger (1993) RCT + + + − + + 1 Rickels (2016) RCT + + + + + + 0 Sherr (2016) RCT + + + + + + 0 Suico (2019) RCT ?”
Stenninger, E., & Åman, J. (1993) · Diabetologia · doi:10.1007/bf02374475 · Cited by 29 · cited 2×
“+ + − + + 2 Slama (1992) RCT + + + + + + 0 Rosenfalck (1992) RCT + + + − + + 1 Stenninger (1993) RCT + + + − + + 1 Rickels (2016) RCT + + + + + + 0 Sherr (2016) RCT + + + + + + 0 Suico (2019) RCT ?”
Guzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28
A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon
Slama, G., Alamowitch, C., Desplanque, N., Letanoux, M., & Zirinis, P. (1990) · Diabetologia · doi:10.1007/bf00400568 · Cited by 27 · cited 2×
“Pontiroli (1989) IM 15 15 35 ± 4 35 ± 4 45 ± 20 55 ± 20 14 (93) 14 (93) Slama (1990)a SC 3 3 30 ± 8 30 ± 8 38 ± 20 41 ± 20 3 (100) 3 (100) Slama (1992) SC 13 7 13 ± 3 13 ± 3 43 ± 15 58 ± 15 12 (92) 6 (86) Rosenfalck (1992)a IM 12 12 31 ± 2 31 ± 2 29 ± 6 29 ± 6 12 (100) 12 (100) Stenninger (1993)a…”
BackgroundIDDM patients' opinions on the use of glucagon emergency kit in severe episodes of hypoglycaemia
Yanai, O., Phillip, M., Harman, I., Leiberman, E., & Pilpel, D. (1997) · Practical Diabetes · doi:10.1002/pdi.1960140204 · Cited by 22
Slama, G. (1992) · Diabetologia · doi:10.1007/bf00401209 · Cited by 18 · cited 2×
“Pontiroli (1989) IM 15 15 35 ± 4 35 ± 4 45 ± 20 55 ± 20 14 (93) 14 (93) Slama (1990)a SC 3 3 30 ± 8 30 ± 8 38 ± 20 41 ± 20 3 (100) 3 (100) Slama (1992) SC 13 7 13 ± 3 13 ± 3 43 ± 15 58 ± 15 12 (92) 6 (86) Rosenfalck (1992)a IM 12 12 31 ± 2 31 ± 2 29 ± 6 29 ± 6 12 (100) 12 (100) Stenninger (1993)a…”
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dci16-0025 · Cited by 13 · cited 2×
“+ + − + + 2 Slama (1992) RCT + + + + + + 0 Rosenfalck (1992) RCT + + + − + + 1 Stenninger (1993) RCT + + + − + + 1 Rickels (2016) RCT + + + + + + 0 Sherr (2016) RCT + + + + + + 0 Suico (2019) RCT ?”
Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B. K., Sherr, J. L., Zijlstra, E., Frier, B. M., Plum‐Mörschel, L., & Mönnig, E. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/s-0039-1688217 · Cited by 4
10-LB: Factors Associated with Fear of Hypoglycemia among the T1D Exchange Glu Population
Liu, J., Mitchell, B. D., Bispham, J. A., Fan, L., Hughes, A. S., & McAuliffe‐Fogarty, A. H. (2019) · Diabetes · doi:10.2337/db19-10-lb · Cited by 3
13-LB: Nasal vs. Injected Glucagon: User Experience Results of a Simulated Severe Hypoglycemia Study
Settles, J. A., Child, C. J., Bajpai, S., Spaepen, E., & Suico, J. G. (2019) · Diabetes · doi:10.2337/db19-13-lb · Cited by 3 · cited 1×
“1 3 that injected glucagon, in contrast to IN glucagon [41–43], is very difficult to administer, and a quite recent study showed that IN glucagon was similarly effective in the hands of caregivers of T1DM patients with or without training, while IM glucagon was much less effective in untrained than in trained caregive…”
Background
Research works printed but not linked: 1
- Centers for Disease Control and Prevention (CDC) (2011) National diabetes fact sheet: national estimates, general information on diabetes, prediabetes in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta
Cited by
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 141
“A recent meta-analysis indicated that intranasal glucagon and SC/IM glucagon were equally effective in resolution of hypoglycemia in conscious individuals.(166) Intranasal”
BackgroundLu, B., GhavamiNejad, A., Liu, J. F., Li, J., Mirzaie, S., Giacca, A., & Wu, X. Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c24955 · Cited by 31
Glucagon use by U.S. adults with type 1 and type 2 diabetes
Kahn, P. A., Liu, S., McCoy, R., Gabbay, R. A., & Lipska, K. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107882 · Cited by 27
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
“This meta-analysis indicated that in patients with T1DM intranasal as well as intramuscular/subcutaneous glucagon were equally effective in resolving hypoglycaemia.(73)”
Metadata
- Authors
- Pontiroli, A. E., & Tagliabue, E.
- Affiliations
- University of Milan (IT)
- MultiMedica (IT)
- Corresponding author
- Pontiroli, Antonio E.
- Venue
- Acta Diabetologica
- Published
- 2020-02-06
- Volume
- 57
- Issue
- 6
- Pages
- 743-749
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W3004952652
- Cited by
- 25
- References
- 50
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 5 · 2022: 9 · 2021: 4
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministero della Salute (ricerca corrente)
- Università degli Studi di Milano (not applicable)
- gruppo Multimedica (not applicable)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, type 1 diabetes, severe hypoglycemia, unconscious patients, third-party assistance
- MeSH terms
- Administration, Intranasal, Blood Glucose, Diabetes Mellitus, Type 1, Glucagon, Humans, Hypoglycemia, Injections, Intramuscular, Injections, Subcutaneous, Insulin, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.